Shirin Shafazand is a Respiratory physician affiliated with University of Miami. OpenAlex indexes 120 publications with 2,538 citations (h-index 22); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1611 NW 12th Ave
Box 016960 M851
Miami, FL 331361005
Telephone
305-585-1111Registry record last updated 13 Feb 2014.
Clinical trials
- Motor Plasticity, Intermittent Hypoxia and Sleep Apnea
Sponsor: University of Miami
- Sleep-Disordered Breathing in Chronic SCI
Sponsor: University of Miami
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20252 payments$28,300openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
- Resmed CorpProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
50%Phosphodiesterase 5 Inhibitor50%Sildenafil Citrate75%Tadalafil25%Part D<11 patientsCardiovascular
38%Endothelin Receptor Antagonist38%Ambrisentan100%Part D≥11 patientsBlood & clotting
7.1%Prostacyclin Receptor Agonist7.1%Uptravi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Harnessing Machine Learning, a Subset of Artificial Intelligence, for Early Detection and Diagnosis of Type 1 Diabetes: A Systematic Review
International Journal of Molecular Sciences
2025 - Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Respiratory Research
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Carlos Singer
University of Miami
Jay Spiegel, MD
University of Miami
Kara Cavuoto, MD
University of Miami
Sixto Arias, MD
University of Miami
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”